This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

52/100

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Risk factors

Topic: Risk, prevention and care in population studies

Among 87,229 matched patients per cohort, GLP-1 RA use was associated with a significantly lower risk of overall dementia (adjusted HR (AHR) 0.90; 95% CI 0.85 to 0.95), Alzheimer's disease (AD) (AHR 0.88; 95% CI 0.83 to 0.94), and non-vascular dementias (non-VaDs) (AHR 0.75; 95% CI 0.70 to 0.81) compared with metformin. No significant difference was observed for VaD. Subgroup analyses showed consistent benefit across age and sex, with the strongest effect among older adults and females. GLP-1 RAs were more effective than metformin in reducing the risk of dementia-especially AD and non-vascular types-highlighting their potential as a preferred first-line treatment in T2DM. Further randomized trials are warranted to validate these findings.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., et al. (2025). Evaluating GLP-1 receptor agonists versus metformin as first-line therapy for reducing dementia risk in type 2 diabetes. BMJ Open Diabetes Research & Care. https://doi.org/10.1136/bmjdrc-2025-004902

Vancouver

Sun M, Wang X, Lu Z, Yang Y, Lv S, Miao M, et al. Evaluating GLP-1 receptor agonists versus metformin as first-line therapy for reducing dementia risk in type 2 diabetes. BMJ Open Diabetes Research & Care. 2025. doi:10.1136/bmjdrc-2025-004902. PMID: 40695613.

BibTeX

@article{sun2025-40695613,
  author  = {Sun, Mingyang and Wang, Xiaoling and Lu, Zhongyuan and Yang, Yi and Lv, Shuang and Miao, Mengrong and Chen, Wanming and Wu, Szu‐Yuan and others},
  title   = {{Evaluating GLP-1 receptor agonists versus metformin as first-line therapy for reducing dementia risk in type 2 diabetes}},
  journal = {BMJ Open Diabetes Research \& Care},
  year    = {2025},
  doi     = {10.1136/bmjdrc-2025-004902},
  pmid    = {40695613},
  url     = {https://doi.org/10.1136/bmjdrc-2025-004902}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Among 87,229 matched patients per cohort, GLP-1 RA use was associated with a significantly lower risk of overall dementia (adjusted HR (AHR) 0.90; 95% CI 0.85 to 0.95), Alzheimer's disease (AD) (AHR 0.88; 95% CI 0.83 to 0.94), and non-vascular dementias (non-VaDs) (AHR 0.75; 95% CI 0.70 to 0.81) compared with metformin.
No significant difference was observed for VaD.
Subgroup analyses showed consistent benefit across age and sex, with the strongest effect among older adults and females.
GLP-1 RAs were more effective than metformin in reducing the risk of dementia-especially AD and non-vascular types-highlighting their potential as a preferred first-line treatment in T2DM.
Further randomized trials are warranted to validate these findings.

Why it matters

In this cohort study, people with type 2 diabetes taking GLP-1 receptor agonists had a lower risk of overall dementia, Alzheimer's disease, and non-vascular dementias compared with those taking metformin, but there was no significant difference for vascular dementia. The authors say randomized trials are needed to confirm these findings before GLP-1 receptor agonists could be considered a preferred first-line treatment.

New to this subject? Start with our plain-English guide: Risk factors, ranked →

Study details

Study designcohort study
Effect sizeAHR 0.88; AHR 0.75
Evidence strengthHigh

How this study scored 52/100

Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for sample size, studied in people and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (BMJ Open Diabetes Research & Care)
Journal's citation record	1 / 4	BMJ Open Diabetes Research & Care: journal h-index 85 (OpenAlex, 2026-10-29)
Study design	7 / 12	A cohort study following people over time
Strength of evidence	5 / 5	Rated “high” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	2 / 3	Effect reported as a number, without an interval or test
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	2 / 7	Cited 12 times (OpenAlex, 2026-10-10)
Citations per year	2 / 5	4.0 citations a year over 3 year(s) since 2025
Impact for its field and year	3 / 6	Cited 7.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	1 / 4	Cited 12 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Jiaqiang Zhang: h-index 29 (OpenAlex, whole career)
Institution's track record	0 / 3	Zhengzhou University: institution h-index 522 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 5 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 40695613)
Free to read	2 / 2	Free to read
Total	52 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Risk factors

Also tagged “double-blind”

783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Similar studies

More on Risk factors

See all studies in Risk factors →